Immunotherapy Archives

den bosch netherlands lava therapeutics cancer immunotherapy

Startup Scout 23 Nov 2018

This Biotech Arms Tumor-Busting Cells to Treat Cancer

In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […]

November 23, 2018 - 3 minutesmins - By Jonathan Smith

More News! 22 Nov 2018

First Drug for Rare Inflammation Syndrome Approved by FDA

The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]

November 22, 2018 - 2 minutesmins - By Jonathan Smith

genentech immunocore immunotherapy pipette

News and Trends 20 Nov 2018

Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy

Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore’s immunotherapy for treating solid tumors. In the agreement, Genentech, a member of the Roche group, will pay UK-based Immunocore €87.3M ($100M) in an upfront payment and further undisclosed milestone payments as the immunotherapy progresses towards […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

More News! 12 Nov 2018

This UK Biotech Wants to Make Antibodies Easy to Swallow

Say goodbye to painful antibody injections. The UK biotech Intract Pharma has received a €1.6M grant to advance oral immunotherapy based on approved antibodies, causing less discomfort for patients. The grant, awarded by public agency Innovate UK, will help Intract develop oral versions of existing antibody therapies. This could make the treatments easier for patients […]

November 12, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2018

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

Interview 25 Oct 2018

Mastering the Competitive World of Immuno-oncology

In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder of NBE Therapeutics, a company using antibody drug conjugates to target cancer, discussed how to navigate the competitive area of immuno-oncology at our […]

October 25, 2018 - 5 minutesmins - By Helen Albert

Innate Pharma Cancer immunotherapy header

News and Trends 22 Oct 2018

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating recurrent squamous cell carcinoma as standard therapy in a Phase II trial. Squamous cell carcinoma is a head and neck cancer that forms lesions in the mucous membranes of body cavities such as the mouth, nose and throat. “Patients are […]

October 22, 2018 - 2 minutesmins - By Jonathan Smith

Immunicum cancer immunotherapy dendritic cell

News and Trends 16 Oct 2018

Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

The Swedish biotech Immunicum has issued shares worth up to almost €34M on Nasdaq Stockholm, in an effort to accelerate the development of its cancer immunotherapy. Immunicum plans to use most of the funding to run a Phase Ib/II clinical trial that will test its lead cell therapy candidate in combination with checkpoint inhibitors to […]

October 16, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2018

Cancer Immunotherapy Phase I on Hold After Patient Death

The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […]

October 10, 2018 - 2 minutesmins - By Jonathan Smith

Boehringer Ingelheim ViraTherapeutics oncolytic virus

More News! 13 Sep 2018

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […]

September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Helen Tayton Martin Adaptimmune interview

Interview 11 Sep 2018

How To Break Into The Crowded Immuno-Oncology Space

The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […]

September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2018

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B

The German biotech will partner with Genentech, part of the Roche Group, to develop targeted cancer therapies that engage both innate and adaptive immune cells. Affimed will receive €82M ($96M) upfront from the US giant to develop its immunotherapy ROCK (Redirected Optimized Cell Killing) platform, which uses both natural killer cells and T-cells to target […]

August 29, 2018 - 2 minutesmins - By Helen Albert

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

This Biotech Arms Tumor-Busting Cells to Treat Cancer

First Drug for Rare Inflammation Syndrome Approved by FDA

Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy

This UK Biotech Wants to Make Antibodies Easy to Swallow

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

Mastering the Competitive World of Immuno-oncology

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

Cancer Immunotherapy Phase I on Hold After Patient Death

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

How To Break Into The Crowded Immuno-Oncology Space

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!